Recent Trends in Therapeutic Drug Monitoring of Peptide Antibiotics.
capillary electrophoresis
clinical outcomes
liquid chromatography
peptide antibiotics
therapeutic drug monitoring
Journal
Journal of separation science
ISSN: 1615-9314
Titre abrégé: J Sep Sci
Pays: Germany
ID NLM: 101088554
Informations de publication
Date de publication:
Oct 2024
Oct 2024
Historique:
revised:
17
09
2024
received:
04
08
2024
accepted:
19
09
2024
medline:
14
10
2024
pubmed:
14
10
2024
entrez:
14
10
2024
Statut:
ppublish
Résumé
Antimicrobial peptides take a specific position in the field of antibiotics (ATBs), however, from a large number of available molecules only a few of them were approved and are used in clinics. These therapeutic modalities play a crucial role in the management of diseases caused by multidrug-resistant bacterial pathogens and represent the last-line therapy for bacterial infections. Therefore, there is a demand for a rationale use of such ATBs based on optimization of the dosing strategy to minimize the risk of resistance and ensure the sustainable efficacy of the drug in real clinical practice. Therapeutic drug monitoring, as a measurement of drug concentration in the body fluids or tissues, results in the optimization of the patient´s medication and therapy outcome. This strategy is beneficial and could result in tailored therapy for different types of infection and the prolongation of the use and efficacy of ATBs in hospitals. This review paper provides an actual overview of approved antimicrobial peptides used in clinical practice and covers current trends in their analysis by convenient and advanced methodologies used for their identification and/or quantitation in biological matrices for therapeutic drug monitoring purposes. Special emphasis is given to the methods with perspective clinical outcomes.
Identifiants
pubmed: 39400453
doi: 10.1002/jssc.202400583
doi:
Substances chimiques
Anti-Bacterial Agents
0
Antimicrobial Peptides
0
Peptides
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e202400583Subventions
Organisme : Ministerstvo školstva, vedy, výskumu a športu Slovenskej republiky
ID : VEGA. 1/0302/24
Informations de copyright
© 2024 Wiley‐VCH GmbH.
Références
E. M. Halawa, M. Fadel, M. W. Al‐Rabia, et al., “Antibiotic Action and Resistance: Updated Review of Mechanisms, Spread, Influencing Factors, and Alternative Approaches for Combating Resistance,” Frontiers in Pharmacology 14 (2023): 1305294.
L. Katz and R. H. Baltz, “Natural Product Discovery: Past, Present, and Future,” Journal of Industrial Microbiology and Biotechnology 43 (2016): 155–176.
M. I. Hutchings, A. W. Truman, and B. Wilkinson, “Antibiotics: Past, Present and Future,” Current Opinion in Microbiology 51 (2019): 72–80.
J. F. Prescott, “The Resistance Tsunami, Antimicrobial Stewardship, and the Golden Age of Microbiology,” Veterinary Microbiology 171 (2014): 273–278.
R. Vivas, A. A. T. Barbosa, S. S. Dolabela, and S. Jain, “Multidrug‐Resistant Bacteria and Alternative Methods to Control Them: An Overview,” Microbial Drug Resistance 25 (2019): 890–908.
L. Chen, S. Kumar, and H. Wu, “A Review of Current Antibiotic Resistance and Promising Antibiotics With Novel Modes of Action to Combat Antibiotic Resistance,” Archives of Microbiology 205 (2023): 356.
A. Tagliabue and R. Rappuoli, “Changing Priorities in Vaccinology: Antibiotic Resistance Moving to the Top,” Frontiers in Immunology 9 (2018): 1068.
D. J. Payne, M. N. Gwynn, D. J. Holmes, and D. L. Pompliano, “Drugs for Bad Bugs: Confronting the Challenges of Antibacterial Discovery,” Nature Reviews Drug Discovery 6 (2006): 29–40.
X. Bian, X. Qu, J. Zhang, et al., “Pharmacokinetics and Pharmacodynamics of Peptide Antibiotics,” Advanced Drug Delivery Reviews 183 (2022): 114171.
A. Moretta, C. Scieuzo, A. M. Petrone, et al., “Antimicrobial Peptides: A New Hope in Biomedical and Pharmaceutical Fields,” Frontiers in Cellular and Infection Microbiology 11 (2021): 668632.
G. S. Dijksteel, M. M. W. Ulrich, E. Middelkoop, and B. Boekema, “Review: Lessons Learned From Clinical Trials Using Antimicrobial Peptides (AMPs),” Frontiers in Microbiology 12 (2021): 616979.
Y. A. S. Guevara, M. H. C. Santos, F. I. R. Gomes, Sheheryar, F. P. Mesquita, and P. F. N. Souza, “A Historical, Economic, and Technical‐Scientific Approach to the Current Crisis in the Development of Antibacterial Drugs: Promising Role of Antibacterial Peptides in this Scenario,” Microbiology Pathology 179 (2023): 106108.
K. Browne, S. Chakraborty, R. Chen, et al., “A New Era of Antibiotics: The Clinical Potential of Antimicrobial Peptides,” International Journal of Molecular Sciences 21 (2020): 7047.
A. Mazurkiewicz‐Pisarek, J. Baran, and T. Ciach, “Antimicrobial Peptides: Challenging Journey to the Pharmaceutical, Biomedical, and Cosmeceutical Use,” International Journal of Molecular Sciences 24 (2023): 9031.
K. P. Sreelakshmi, M. Madhuri, R. Swetha, V. Rangarajan, and U. Roy, “Microbial Lipopeptides: Their Pharmaceutical and Biotechnological Potential, Applications, and Way Forward,” World Journal of Microbiology and Biotechnology 40 (2024): 135.
F. Sjövall, C. Lanckohr, and H. Bracht, “What's New in Therapeutic Drug Monitoring of Antimicrobials?,” Intensive Care Medicine 49 (2023): 857–859.
N. Brasier, H. C. Ates, J. R. Sempionatto, et al., “A Three‐Level Model for Therapeutic Drug Monitoring of Antimicrobials at the Site of Infection,” Lancet Infectious Diseases 10 (2023): E445–E453.
K. Moorthy, K.‐C. Chang, H.‐H. Yang, W.‐M. Su, C.‐K. Chiang, and Z. Yuan, “Recent Developments in Detection and Therapeutic Approaches for Antibiotic‐Resistant Bacterial Infections,” Journal of Food and Drug Analysis 31 (2023): 1.
J.‐S. Kang and M.‐H. Lee, “Overview of Therapeutic Drug Monitoring,” Korean Journal of Internal Medicine 24 (2009): 1–10.
G. Voulgaridou, T. Paraskeva, G. Ragia, et al., “Therapeutic Drug Monitoring (TDM) Implementation in Public Hospitals in Greece in 2003 and 2021: A Comparative Analysis of TDM Evolution Over the Years,” Pharmaceutics 15 (2023): 2181.
A. Cafaro, S. Barco, F. Pigliasco, et al., “Therapeutic Drug Monitoring of Glycopeptide Antimicrobials: An Overview of Liquid Chromatography‐Tandem Mass Spectrometry Methods,” Journal of Mass Spectrometry and Advances in the Clinical Lab 31 (2024): 33–39.
S. O. Bekoe, S. Asare‐Nkansah, and K. F. M Opuni, “Analytical Techniques for Therapeutic Drug Monitoring and Clinical Toxicology,” in Recent Advances in Therapeutic Drug Monitoring and Clinical Toxicology, eds. S. K. Amponsah and Y. V. Pathak (Cham: Springer, 2022), 9–22.
W. Clarke, “Immunoassays for Therapeutic Drug Monitoring and Clinical Toxicology,” in Handbook of Analytical Separations, ed. G. Hempel (Amsterdam: Elsevier), 97–114.
M. Shipkova, D. T. Petrova, A. E. Rosler, et al., “Comparability and Imprecision of 8 Frequently Used Commercially Available Immunoassays for Therapeutic Drug Monitoring,” Therapeutic Drug Monitoring 36 (2014): 433–441.
J. Diana, D. Visky, J. Hoogmartens, A. Van Schepdael, and E. Adams, “Investigation of Vancomycin and Related Substances by Liquid Chromatography/Ion Trap Mass Spectrometry,” Rapid Communications in Mass Spectrometry 20 (2006): 685–693.
M. E. Hadwiger, C. D. Sommer, D. J. Mans, V. Patel, and M. T. Boyne, “Quality Assessment of U.S. Marketplace Vancomycin for Injection Products Using High‐Resolution Liquid Chromatography‐Mass Spectrometry and Potency Assays,” Antimicrobial Agents and Chemotherapy 56 (2012): 2824–2830.
S. Nambiar, R. D. Madurawe, S. M. Zuk, et al., “Product Quality of parenteral Vancomycin Products in the United States,” Antimicrobial Agents and Chemotherapy 56 (2012): 2819–2823.
S. Junger, M. Hoene, M. Shipkova, et al., “Automatd LC‐MS/MS: Ready for the Clinical Routine Laboratory?,” Journal of Mass Spectrometry and Advances in the Clinical Lab 30 (2023): 1–9.
A. Unlu and S. Abusoglu, “Clinical Laboratory Use of Liquid Chromatography Mass Spectrometry,” Turkish Journal of Biochemistry 47 (2022): 548–556.
B. A. Rappold, “Review of the Use of Liquid Chromatography‐Tandem Mass Spectrometry in Clinical Laboratories: Part II—Operations,” Annals of Laboratory Medicine 42 (2022): 531–557.
J. Piestansky, P. Barath, P. Majerova, et al., “A Simple and Rapid LC‐MS/MS and CE‐MS/MS Analytical Strategy for the Determination of Therapeutic Peptides in Modern Immunotherapeutics and Biopharmaceutics,” Journal of Pharmaceutical and Biomedical Analysis 189 (2020): 113449.
Y. Yang, X. Bao, J. Ning, et al., “A Sensitive and Specific LC–MS/MS Method for Determination of a Novel Antihypertensive Peptide FR‐6 in Rat Plasma and Pharmacokinetic Study,” Heliyon 10 (2024): e26209.
M. Rauh, “LC‐MS/MS for Protein and Peptide Quantification in Clinical Chemistry,” Journal of Chromatography B 883–884 (2012): 59–67.
H. S. Oh, M. Choi, T. S. Lee, et al., “Pharmacokinetics and Brain Distribution of the Therapeutic Peptide Liraglutide by a Novel LC–MS/MS Analysis,” Journal of Analytical Science and Technology 14 (2023): 19.
O. Stefanik, P. Majerova, A. Kovac, P. Mikus, and J. Piestansky, “Capillary Electrophoresis in the Analysis of Therapeutic Peptides—A Review,” Electrophoresis 45 (2024): 120–164.
V. Kašička, “Recent Developments in Capillary and Microchip Electroseparations of Peptides (2021–mid‐2023),” Electrophoresis 45 (2024): 165–198.
N. Niaei, M. Vališ, and J. Petr, “Capillary Zone Electrophoresis Method for Quantification of Therapeutic Peptide Glatiramer Acetate,” Monatshefte Fuer Chemie 155 (2024): 441–446.
J. Piestansky, I. Cizmarova, O. Stefanik, et al., “Capillary Electrophoresis‐Mass Spectrometry With Multisegment Injection and In‐Capillary Preconcentration for High‐Throughput and Sensitive Determination of Therapeutic Decapeptide Triptorelin in Pharmaceutical and Biological Matrices,” Biomedicines 9 (2021): 1488.
I. Miksik, “Coupling of CE‐MS for Protein and Peptide Analysis,” Journal of Separation Science 42 (2019): 385–397.
V. Kašička, “Recent Developments in Capillary and Microchip Electroseparations of Peptides (2017‐Mid 2019),” Electrophoresis 41 (2020): 10–35.
V. Kašička, “Recent Developments in Capillary and Microchip Electroseparations of Peptides (2019‐Mid 2021),” Electrophoresis 43 (2022): 82–108.
H. Mischak, A. Vlahou, and J. P. A. Ioannidis, “Technical Aspects and Inter‐Laboratory Variability in Native Peptide Profiling: The CE–MS Experience,” Clinical Biochemistry 46 (2013): 432–443.
R. G. Benedict and A. F. Langlykke, “Antibiotic Activity of Bacillus Polymyxa,” Journal of Bacteriology 54 (1947): 24.
P. G. Stansly, “The Polymyxins: A Review and Assessment,” American Journal of Medicine 7 (1949): 807–818.
L. Poirel, A. Jayol, and P. Nordmann, “Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes,” Clinical Microbiology Reviews 30 (2017): 557–596.
S. C. Nang, M. A. K. Azad, T. Velkov, Q. T. Zhou, and J. Li, “Rescuing the Last‐Line Polymyxins: Achievements and Challenges,” Pharmacological Reviews 73 (2021): 679–728.
T. Velkov, P. E. Thompson, R. L. Nation, and J. Li, “Structure–Activity Relationships of Polymyxin Antibiotics,” Journal of Medicinal Chemistry 53 (2010): 1898–1916.
C. Govaerts, J. Orwa, A. Van Schepdael, E. Roets, and J. Hoogmartens, “Characterization of Polypeptide Antibiotics of the Polymyxin Series by Liquid Chromatography Electrospray Ionization Ion Trap Tandem Mass Spectrometry,” Journal of Peptide Science: Official Journal of the European Peptide Society 8 (2002): 45–55.
C. Govaerts, J. Orwa, A. Van Schepdael, E. Roets, and J. Hoogmartens, “Liquid Chromatography‐Ion Trap Tandem Mass Spectrometry for the Characterization of Polypeptide Antibiotics of the Colistin Series in Commercial Samples,” Journal of Chromatography A 976 (2002): 65–78.
J. A. Orwa, C. Govaerts, R. Busson, E. Roets, A. Van Schepdael, and J. Hoogmartens, “Isolation and Structural Characterization of Colistin Components,” Journal of Antibiotics 54 (2001): 595–599.
J. A. Orwa, C. Govaerts, R. Busson, E. Roets, A. Van Schepdael, and J. Hoogmartens, “Isolation and Structural Characterization of Polymyxin B Components,” Journal of Chromatography A 912 (2001): 369–373.
A. Clausell, M. Garcia‐Subirats, M. Pujol, M. A. Busquets, F. Rabanal, and Y. Cajal, “Gram‐Negative Outer and Inner Membrane Models: Insertion of Cyclic Cationic Lipopeptides,” Journal of Physical Chemistry B 111 (2007): 551–563.
M. A. Kohanski, D. J. Dwyer, B. Hayete, C. A. Lawrence, and J. J. Collins, “A Common Mechanism of Cellular Death Induced by Bactericidal Antibiotics,” Cell 130 (2007): 797–810.
A. C. Gales, R. N. Jones, and H. S. Sader, “Contemporary Activity of Colistin and Polymyxin B Against a Worldwide Collection of Gram‐Negative Pathogens: Results From the SENTRY Antimicrobial Surveillance Program (2006‐09),” Journal of Antimicrobial Chemotherapy 66 (2011): 2070–2074.
P. D. Tamma, S. L. Aitken, R. A. Bonomo, A. J. Mathers, D. van Duin, and C. J. Clancy, “Infectious Diseases Society of America Guidance on the Treatment of AmpC β‐Lactamase‐Producing Enterobacterales, Carbapenem‐Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections,” Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 74 (2022): 2089–2114.
P. D. Tamma, S. L. Aitken, R. A. Bonomo, A. J. Mathers, D. van Duin, and C. J. Clancy, “Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended‐Spectrum β‐Lactamase Producing Enterobacterales (ESBL‐E), Carbapenem‐Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa With Difficult‐To‐Treat Resistance (DTR‐P. aeruginosa),” Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 75 (2022): 187–212.
B. T. Tsuji, J. M. Pogue, A. P. Zavascki, et al., “International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐Infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP),” Pharmacotherapy 39 (2019): 10–39.
R. L. Nation, T. Velkov, and J. Li, “Colistin and Polymyxin B: Peas in a Pod, or Chalk and Cheese?,” Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 59 (2014): 88–94.
R. L. Nation, J. Li, O. Cars, et al., “Framework for Optimisation of the Clinical Use of Colistin and Polymyxin B: The Prato polymyxin Consensus,” Lancet Infectious Diseases 15 (2015): 225–234.
P. Y. Robert and J. P. Adenis, “Comparative Review of Topical Ophthalmic Antibacterial Preparations,” Drugs 61 (2001): 175–185.
J. Li, R. W. Milne, R. L. Nation, J. D. Turnidge, T. C. Smeaton, and K. Coulthard, “Pharmacokinetics of Colistin Methanesulphonate and Colistin in Rats Following an Intravenous Dose of Colistin Methanesulphonate,” Journal of Antimicrobial Chemotherapy 53 (2004): 837–840.
Y. Dubrovskaya, N. Prasad, Y. Lee, D. Esaian, D. A. Figueroa, and V. H. Tam, “Risk Factors for Nephrotoxicity Onset Associated With polymyxin B Therapy,” Journal of Antimicrobial Chemotherapy 70 (2015): 1903–1907.
L. Sorlí, S. Luque, S. Grau, et al., “Trough Colistin Plasma Level Is an Independent Risk Factor for Nephrotoxicity: A Prospective Observational Cohort Study,” BMC Infectious Diseases [Electronic Resource] 13 (2013): 380.
M. E. Falagas and S. K. Kasiakou, “Toxicity of Polymyxins: A Systematic Review of the Evidence From Old and Recent Studies,” Critical Care (London, England) 10 (2006): R27.
Y. M. Li, C. Milikowski, G. Selvaggi, L. M. Abbo, D. Skiada, and F. Galimberti, “Polymyxin B‐Induced Skin Hyperpigmentation,” Transplant Infectious Disease: An Official Journal of the Transplantation Society 22 (2020): e13312.
M. Biagi, D. Butler, X. Tan, S. Qasmieh, and E. Wenzler, “A Breath of Fresh Air in the Fog of Antimicrobial Resistance: Inhaled Polymyxins for Gram‐Negative Pneumonia,” Antibiotics 8 (2019): 27.
M. Heidary, A. D. Khosravi, S. Khoshnood, M. J. Nasiri, S. Soleimani, and M. Goudarzi, “Daptomycin,” Journal of Antimicrobial Chemotherapy 73 (2018): 1–11.
M. Debono, B. J. Abbott, R. M. Molloy, et al., “Enzymatic and Chemical Modifications of Lipopeptide Antibiotic A21978C: The Synthesis and Evaluation of Daptomycin (LY146032),” Journal of Antibiotics 4 (1988): 1093–1105.
S. W. Ho, D. Jung, J. R. Calhoun, et al., “Effect of Divalent Cations on the Structure of the Antibiotic Daptomycin,” European Biophysics Journal 37 (2008): 421–433.
A. L. Barry, P. C. Fuchs, and S. D. Brown, “In Vitro Activities of Daptomycin Against 2,789 Clinical Isolates From 11 North American Medical Centers,” Antimicrobial Agents and Chemotherapy 45 (2001): 1919–1922.
J. M. Streit, R. N. Jones, and H. S. Sader, “Daptomycin Activity and Spectrum: A Worldwide Sample of 6737 Clinical Gram‐Positive Organisms,” Journal of Antimicrobial Chemotherapy 53 (2004): 669–674.
A. Gonzalez‐Ruiz, P. Gargalianos‐Kakolyris, A. Timerman, et al., “Daptomycin in the Clinical Setting: 8‐Year Experience With Gram‐Positive Bacterial Infections From the EU‐CORESM Registry,” Advances in Therapy 32 (2015): 496–509.
R. A. Seaton, V. J. Gonzalez‐Ramallo, V. Prisco, et al., “Daptomycin for Outpatient Parenteral Antibiotic Therapy: A European Registry Experience,” International Journal of Antimicrobial Agents 41 (2013): 468–472.
M. Abbas, M. Paul, and A. Huttner, “New and Improved? A Review of Novel Antibiotics for Gram‐Positive Bacteria,” Clinical Microbiology and Infection 23 (2017): 697–703.
P. E. Reynolds, “Structure, Biochemistry and Mechanism of Action of Glycopeptide Antibiotics,” European Journal of Clinical Microbiology & Infectious Diseases: Official Publication of the European Society of Clinical Microbiology 8 (1989): 943–950.
D. P. Levine, “Vancomycin: A History,” Clinical Infectious Diseases 42 (2006): S5–12.
Vancomycin. Lancet 1957; 269: 85–86.
C. M. Harris and T. M. Harris, “Structure of the Glycopeptide Antibiotic Vancomycin. Evidence for an Asparagine Residue in the Peptide,” Journal of the American Chemical Society 104 (1982): 4293–4295.
R. S. Griffith, “Introduction to vancomycin,” Reviews of Infectious Diseases 3 (1981): S200–204.
E. Rubinstein and Y. Keynan, “Vancomycin Revisited –60 Years Later,” Front Public Health 2 (2014): 217.
G. R. Bailie and D. Neal, “Vancomycin Ototoxicity and Nephrotoxicity. A Review,” Medical Toxicology and Adverse Drug Experience 3 (1988): 376–386.
P. G. Traber and D. P. Levine, “Vancomycin Ototoxicity in Patient With Normal Renal Function,” Annals of Internal Medicine 95 (1981): 458–460.
A. Forouzesh, P. A. Moise, and G. Sakoulas, “Vancomycin Ototoxicity: A Reevaluation in an Era of Increasing Doses,” Antimicrobial Agents and Chemotherapy 53 (2009): 483–486.
R. E. Brummett and K. E. Fox, “Vancomycin‐ and Erythromycin‐Induced Hearing Loss in Humans,” Antimicrobial Agents and Chemotherapy 33 (1989): 791–796.
L. P. Rybak, V. Ramkumar, and D. Mukherjee, “Ototoxicity of Non‐Aminoglycoside,” Antibiotics Frontiers in Neurology 12 (2021): 652674.
E. Filippone, W. Kraft, and J. Farber, “The Nephrotoxicity of Vancomycin,” Clinical Pharmacology & Therapeutics 102 (2017): 459–469.
R. E. Polk, D. P. Healy, L. B. Schwartz, D. T. Rock, M. L. Garson, and K. Roller, “Vancomycin and the Red‐Man Syndrome: Pharmacodynamics of Histamine Release,” Journal of Infectious Diseases 157 (1988): 502–507.
S. K. Fridkin, J. Hageman, L. K. McDougal, et al., “Epidemiological and Microbiological Characterization of Infections Caused by Staphylococcus aureus With Reduced Susceptibility to Vancomycin, United States, 1997–2001,” European Journal of Clinical Microbiology & Infectious Diseases Official Publication of the European Society of Clinical Microbiology 36 (2003): 429–439.
J. C. Barna and D. H. Williams, “The Structure and Mode of Action of Glycopeptide Antibiotics of the Vancomycin Group,” Annual Review of Microbiology 38 (1984): 339–357.
A. J. Brink, G. A. Richards, G. Colombo, F. Bortolotti, P. Colombo, and F. Jehl, “Multicomponent Antibiotic Substances Produced by Fermentation: Implications for Regulatory Authorities, Critically Ill Patients and Generics,” International Journal of Antimicrobial Agents 43 (2014): 1–6.
R. N. Brogden and D. H. Peters, “Teicoplanin. A Reappraisal of Its Antimicrobial Activity, Pharmacokinetic Properties and Therapeutic Efficacy,” Drugs 47 (1994): 823–854.
A. B. Cavalcanti, A. R. Goncalves, C. S. Almeida, D. D. Bugano, and E. Silva, “Teicoplanin versus vancomycin for Proven or Suspected Infection,” Cochrane Database of Systematic Reviews (Online) 6 (2010): CD007022.
G. G. Zhanel, D. Calic, F. Schweizer, et al., “New Lipoglycopeptides: A Comparative Review of dalbavancin, oritavancin and Telavancin,” Drugs 70 (2010): 859–886.
D. L. Higgins, R. Chang, D. V. Debabov, et al., “Telavancin, a Multifunctional Lipoglycopeptide, Disrupts both Cell Wall Synthesis and Cell Membrane Integrity in Methicillin‐Resistant Staphylococcus aureus,” Antimicrobial Agents and Chemotherapy 49 (2005): 1127–1134.
G. G. Zhanel, F. Schweizer, and J. A. Karlowsky, “Oritavancin: Mechanism of Action,” Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 54 (2012): S214–219.
A. Belley, G. A. McKay, F. F. Arhin, et al., “Oritavancin Disrupts Membrane Integrity of Staphylococcus aureus and Vancomycin‐Resistant Enterococci To Effect Rapid Bacterial Killing,” Antimicrobial Agents and Chemotherapy 54 (2010): 5369–5371.
A. Malabarba and B. P. Goldstein, “Origin, Structure, and Activity in Vitro and in Vivo of dalbavancin,” Journal of Antimicrobial Chemotherapy 55 (2005): ii15–20.
Orbactiv, “USA Full Prescribing Information,” https://www.orbactiv.com/pdfs/orbactiv‐prescribing‐information.pdf. Accessed July 17, 2024.
EMA, https://www.ema.europa.eu/en/documents/product‐information/tenkasi‐epar‐product‐information_en.pdf. Accessed July 17, 2024.
EMA, https://www.ema.europa.eu/en/documents/product‐information/xydalba‐epar‐product‐information_en.pdf. Accessed July 17, 2024.
Rxabbvie, “USA Full Prescribing Information,” https://www.rxabbvie.com/pdf/dalvance_pi.pdf. Accessed July 18, 2024.
Vibativ, “USA Full Prescribing Information,” https://www.vibativ.com/wp‐content/uploads/2023/12/Vibativ‐PI‐Nov2023.pdf. Accessed July 18, 2024.
F. F. Arhin, I. Sarmiento, T. R. Parr, and G. Moeck, “Comparative in Vitro Activity of oritavancin Against Staphylococcus aureus Strains That Are Resistant, Intermediate or Heteroresistant to Vancomycin,” Journal of Antimicrobial Chemotherapy 64 (2009): 868–870.
R. N. Jones, H. S. Sader, and R. K. Flamm, “Update of Dalbavancin Spectrum and Potency in the USA: Report From the SENTRY Antimicrobial Surveillance Program (2011),” Diagnostic Microbiology and Infectious Disease 75 (2013): 304–307.
K. Kosowska‐Shick, C. Clark, G. A. Pankuch, et al., “Activity of Telavancin Against staphylococci and Enterococci Determined by MIC and Resistance Selection Studies,” Antimicrobial Agents and Chemotherapy 53 (2009): 4217–4224.
S. L. Barriere, “The ATTAIN Trials: Efficacy and Safety of Telavancin Compared with Vancomycin for the Treatment of Hospital‐Acquired and Ventilator‐Associated Bacterial Pneumonia,” Future Microbiology 9 (2014): 281–289.
S. L. Barriere, “ATLAS Trials: Efficacy and Safety of telavancin Compared With vancomycin for the Treatment of Skin Infections,” Future Microbiology 5 (2010): 1765–1773.
S. Mitra, U. Saeed, D. H. Havlichek, and G. E. Stein, “Profile of Oritavancin and Its Potential in the Treatment of Acute Bacterial Skin Structure Infections,” Infection and Drug Resistance 8 (2015): 189–197.
S. Ramdeen and H. W. Boucher, “Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections,” Expert Opinion on Pharmacotherapy 16 (2015): 2073–2081.
Vibativ, “USA Full Prescribing Information,” https://www.vibativ.com/wp‐content/uploads/2023/12/Vibativ‐PI‐Nov2023.pdf. Accessed July 20, 2024.
Orbactiv, “USA Full Prescribing Information,” https://www.orbactiv.com/pdfs/orbactiv‐prescribing‐information.pdf. Accessed July 20, 2024.
EMA, https://www.ema.europa.eu/en/documents/product‐information/tenkasi‐epar‐product‐information_en.pdf. Accessed July 20, 2024.
EMA, https://www.ema.europa.eu/en/documents/product‐information/xydalba‐epar‐product‐information_en.pdf. Accessed July 20, 2024.
Rxabbvie, “USA Full Prescribing Information,” https://www.rxabbvie.com/pdf/dalvance_pi.pdf. Accessed July 20, 2024.
E. Rubinstein, T. Lalani, G. R. Corey, et al., “Telavancin versus vancomycin for Hospital‐Acquired Pneumonia due to Gram‐Positive Pathogens,” Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 52 (2011): 31–40.
M. E. Stryjewski, D. R. Graham, S. E. Wilson, et al., “Telavancin versus vancomycin for the Treatment of Complicated Skin and Skin‐Structure Infections Caused by Gram‐Positive Organisms,” Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 46 (2008): 1683–1693.
G. R. Corey, S. Good, H. Jiang, et al., “Single‐Dose Oritavancin versus 7–10 Days of Vancomycin in the Treatment of Gram‐Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority Study,” Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 60 (2015): 254–262.
EMA,, https://www.ema.europa.eu/en/documents/product‐information/xydalba‐epar‐product‐information_en.pdf. Accessed July 20, 2024.
Rxabbvie, “USA Full Prescribing Information,” https://www.rxabbvie.com/pdf/dalvance_pi.pdf. Accessed July 20, 2024.
M. T. Rosanova, D. Bes, P. Serrano‐Aguilar, N. Sberna, E. Herrera‐Ramos, and R. L. Lede, “Efficacy and Safety of daptomycin: Systematic Review and Meta‐Analysis,” Therapeutic Advances in Infectious Disease 6 (2019): 2049936119886465.
N. M. Wrong, R. C. Smith, A. L. Hudson, and H. C. Hair, “The Treatment of Pyogenic Skin Infections With Bacitracin Ointment,” Treatment Services Bulletin Canadian Department of Veteran Affairs 6 (1951): 257–261.
J. Zhu, S. Wang, C. Wang, et al., “Microbial Synthesis of Bacitracin: Recent Progress, Challenges, and Prospects,” Synthetic and Systems Biotechnology 8 (2023): 314–322.
K. J. Stone and J. L. Strominger, “Mechanism of Action of Bacitracin: Complexation With Metal Ion and C 55 ‐Isoprenyl Pyrophosphate,” PNAS 68 (1971): 3223–3227.
F. Gigliotti, J. O. Hendley, J. Morgan, R. Michaels, M. Dickens, and J. Lohr, “Efficacy of Topical Antibiotic Therapy in Acute Conjunctivitis in Children,” Journal of Pediatrics 104 (1984): 623–626.
P. C. Schalock and K. A. Zug, “Bacitracin,” Cutis; Cutaneous Medicine for the Practitioner 76 (2005): 105–107.
H. Cronin and C. Mowad, “Anaphylactic Reaction to Bacitracin Ointment,” Cutis; Cutaneous Medicine for the Practitioner 83 (2009): 127–129.
J. A. Killian, “Gramicidin and Gramicidin‐Lipid Interactions,” Biochimica Et Biophysica Acta 1113 (1992): 391–425.
D. Constantin, “Membrane‐Mediated Repulsion Between Gramicidin Pores,” Biochimica Et Biophysica Acta 1788 (2009): 1782–1789.
A. Knopik‐Skrocka and J. Bielawski, “The Mechanism of the Hemolytic Activity of Polyene Antibiotics,” Cellular & Molecular Biology Letters 7 (2002): 31–48.
S. Ji, F. An, T. Zhang, et al., “Antimicrobial Peptides: An Alternative to Traditional Antibiotics,” European Journal of Medicinal Chemistry 265 (2024): 116072.
N. Bostanghadiri, N. Narimisa, M. Mirshekar, et al., “Prevalence of Colistin Resistance in Clinical Isolates of Acinetobacter baumannii: A Systematic Review and Meta‐Analysis,” Antimicrob Resist Infect Control 13 (2024): 24.
J. Sharma, D. Sharma, A. Singh, and K. Sunita, “Colistin Resistance and Management of Drug Resistant Infections,” Canadian Journal of Infectious Diseases and Medical Microbiology 1 (2022): 4315030.
H. A. El‐Mahallawy, M. El Swify, A. A. Hak, and M. M. Zafer, “Increasing Trends of Colistin Resistance in Patients at High‐Risk of Carbapenem‐Resistant Enterobacteriaceae,” Annals of Medicine 54 (2022): 2748–2756.
S. Barnsteiner, F. Baty, W. C. Albrich, et al., “Antimicrobial Resistance and Antibiotic Consumption in Intensive Care Units, Switzerland, 2009 to 2018,” Euro Surveillance 26 (2021): 2001537.
H. Periasamy and A. Gnanamani, “Polymyxins Resistance Among Gram‐Negative Pathogens in India,” Lancet Infectious Diseases 20 (2020): 1362–1363.
P. Leroy, D. Decolin, P. Archimbault, and A. Nicolas, “Residue Determination of Two Co‐Administered Antibacterial Agents—cephalexin and Colistin—in Calf Tissues Using High‐Performance Liquid Chromatography and Microbiological Methods,” Journal of Pharmaceutical and Biomedical Analysis 7 (1989): 1837–1846.
H. C. Ates, J. A. Roberts, J. Lipman, A. E. G. Cass, G. A. Urban, and C. Dincer, “On‐Site Therapeutic Drug Monitoring,” Trends in Biotechnology 38 (2020): 1262–1277.
M. A. Burkin, I. A. Galvidis, Y. A. Surovoy, I. V. Plyushchenko, I. A. Rodin, and S. V. Tsarenko, “Development of ELISA Formats for Polymyxin B Monitoring in Serum of Critically Ill Patients,” Journal of Pharmaceutical and Biomedical Analysis 204 (2021): 114275.
I. A. Galvidis, Y. A. Surovoy, G. S. Perevoznyuk, S. V. Tsarenko, and M. A. Burkin, “Unbound Serum Polymyxin B in Patients With SepsIS: Detection Approaches and Limited Sampling Strategy for Clinical Practice and Research,” Journal of Pharmaceutical and Biomedical Analysis 220 (2022): 114983.
I. Dagla, E. Karkoula, E. Baira, A. Tsarbopoulos, and E. Gikas, “Analytical Methodologies Used for the Determination of Colistin in Biological Fluids. Is It Still a Challenge?,” Journal of Pharmaceutical and Biomedical Analysis 164 (2019): 777–788.
D. W. Sin and Y. Wong, “Analytical Methodologies for Identifying a Polypeptide Antibiotic,” Trends in Analytical Chemistry 22 (2003): 799–809.
S. A. Ranamukhaarachchi, C. Padeste, M. Dübner, U. O. Häfeli, B. Stoeber, and V. J. Cadarso, “Integrated Hollow Microneedle‐Optofluidic Biosensor for Therapeutic Drug Monitoring in Sub‐Nanoliter Volumes,” Scientific Reports 6 (2016): 29075.
D. Corradini, “Buffering Agents and Additives for the Background Electrolyte Solutions Used for Peptide and Protein Capillary Zone Electrophoresis,” Trends in Analytical Chemistry 164 (2023): 117080.
P. Tůma, “Progress in On‐Line, At‐Line, and In‐Line Coupling of Sample Treatment With Capillary and Microchip Electrophoresis Over the Past 10 Years: A Review,” Analytica Chimica Acta 1261 (2023): 341249.
B. Seyfinejad and A. Jouyban, “Capillary Electrophoresis‐Mass Spectrometry in Pharmaceutical and Biomedical Analyses,” Journal of Pharmaceutical and Biomedical Analysis 221 (2022): 115059.
P. Švecová, D. Baron, K. A. Schug, T. Pluháček, and J. Petr, “Ultra‐Trace Determination of Oxaliplatin Impurities by Sweeping‐MEKC‐ICP‐MS,” Microchemical Journal 172 (2022): 106957.
L. H. J. Kleijn and N. I Martin, “The Cyclic Lipopeptide antibiotics,” Top. Med. Chem, eds. Fisher JD, Mobashery, S, Miller MJ (Cham: Springer, 2018), 27–54.
J. Li, R. L. Nation, and K. S Kaye, “Polymyxin Antibiotic: From Laboratory Bench to Bedside,” (Cham, Switzerland: Springer, 2019).
H. K. Kristensen and S. H. Hansen, “Separation of Polymyxins by Micellar Electrokinetic Capillary Chromatography,” Journal of Chromatography A 628 (1993): 309–315.
D. J. Gmur, C. R. Bredl, S. J. Steele, S. Cai, D. R. VanDevanter, and P. A. Nardella, “Determination of Polymyxin E1 in Rat Plasma by High‐Performance Liquid Chromatography,” Journal of Chromatography B 789 (2003): 365–372.
X. Lu, C. Zhong, Y. Liu, et al., “Efficacy and Safety of Polymyxin E Sulfate in the Treatment of Critically Ill Patients With Carbapenem‐Resistant Organism Infections,” Frontiers in Medicine 9 (2022): 1067548.
H. Xu, Y. Li, J. Zhang, et al., “A Quantitative Method for Determination of Colistin E2 Methanesulphonate in Human Plasma by 15N‐Labeled Colistin E2,” Scientific Reports 13 (2023): 18348.
T. Suzuki, K. Hayashi, K. Fujikawa, and K. Tsukamoto, “The Chemical Structure of Polymyxin E: The Identities of Polymyxin E1 With Colistin A and of Polymyxin E2 With Colistin B,” Journal of Biochemistry 57 (1965): 226–227.
Y. Cai, W. Lee, and A. L. Kwa, “Polymyxin B versus colistin: An Update,” Expert Review of Anti‐Infective Therapy 13 (2015): 1481–1497.
J. Rychlíčková, V. Kubíčková, P. Suk, and K. Urbánek, “Challenges of Colistin Use in ICU and Therapeutic Drug Monitoring: A Literature Review,” Antibiotics 12 (2023): 437.
M. S. Zabidi, R. Abu Bakar, N. Musa, and W. N. W. Yusuf, “Analytical Methodologies for Measuring Colistin Levels in Pharmacokinetic Studies,” Journal of Liquid Chromatography and Related Technologies 43 (2020): 671–686.
P. P. H. Le Brun, A. I. de Graaf, and A. Vinks, “High‐Performance Liquid Chromatographic Method for the Determination of Colistin in Serum,” Ther Drug Monitor 22 (2000): 589–593.
J. Li, R. W. Milne, R. L. Nation, J. D. Turnidge, K. Coulthard, and D. W. Johnson, “A Simple Method for the Assay of Colistin in Human Plasma, Using Pre‐Column Derivatization With 9‐Fluorenylmethyl Chloroformate in Solid‐Phase Extraction Cartridges and Reversed‐Phase High‐Performance Liquid Chromatography,” Journal of Chromatography B 761 (2001): 167–175.
J. Li, R. W. Milne, R. L. Nation, J. D. Turnidge, K. Coulthard, and J. Valentine, “Simple Method for Assaying Colistin Methanesulfonate in Plasma and Urine Using High‐Performance Liquid Chromatography,” Antimicrobial Agents and Chemotherapy 46 (2002): 3304–3307.
M. D. Reed, R. C. Stern, M. A. O'Riordan, and J. L. Blumer, “The Pharmacokinetics of Colistin in Patients With Cystic Fibrosis,” Journal of Clinical Pharmacology 41 (2001): 645–654.
B. Jansson, M. Karvanen, O. Cars, D. Plachouras, and L. E. Friberg, “Quantitative Analysis of Colistin A and Colistin B in Plasma and Culture Medium Using a Simple Precipitation Step Followed by LC/MS/MS,” Journal of Pharmaceutical and Biomedical Analysis 49 (2009): 760–767.
Z. Ma, J. Wang, J. P. Gerber, and R. W. Milne, “Determination of Colistin in Human Plasma, Urine and Other Biological Samples Using LC–MS/MS,” Journal of Chromatography B 862 (2008): 205–212.
P. Gobin, F. Lemaître, S. Marchand, W. Couet, and J.‐C. Olivier, “Assay of Colistin and Colistin Methanesulfonate in Plasma and Urine by Liquid Chromatography‐Tandem Mass Spectrometry,” Antimicrobial Agents and Chemotherapy 54 (2010): 1941–1948.
Y. Dotsikas, C. K. Markopoulou, J. E. Koundourellis, and Y. L. Loukas, “Validation of a Novel LC‐MS/MS Method for the Quantitation of Colistin A and B in Human Plasma,” Journal of Separation Science 34 (2011): 37–45.
E. Gikas, F. N. Bazoti, M. Katsimardou, et al., “Determination of Colistin A and Colistin B in Human Plasma by UPLC–ESI High Resolution Tandem MS: Application to a Pharmacokinetic Study,” Journal of Pharmaceutical and Biomedical Analysis 83 (2013): 228–236.
I.‐L. Tsai, H.‐Y. Sun, G.‐Y. Chen, S.‐W. Lin, and C.‐H. Kuo, “Simultaneous Quantification of Antimicrobial Agents for Multidrug‐Resistant Bacterial Infections in Human Plasma by Ultra‐High‐Pressure Liquid Chromatography–Tandem Mass Spectrometry,” Talanta 116 (2013): 593–603.
D. Chepyala, I.‐L. Tsai, H.‐Y. Sun, S.‐W. Lin, and C.‐H. Kuo, “Development and Validation of a High‐Performance Liquid Chromatography‐Fluorescence Detection Method for the Accurate Quantification of Colistin in Human Plasma,” Journal of Chromatography B 980 (2015): 48–54.
M. Leporati, R. O. Bua, F. Mariano, et al., “Determination by LC–MS/MS of Colistins A and B in Plasma and Ultrafiltrate From Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration,” Therapeutic Drug Monitoring 36 (2014): 182–191.
T. Mercier, F. Tissot, C. Gardiol, et al., “High‐Throughput Hydrophilic Interaction Chromatography Coupled to Tandem Mass Spectrometry for the Optimized Quantification of the Anti‐Gram‐Negatives Antibiotic Colistin A/B and Its Pro‐Drug Colistimethate,” Journal of Chromatography A 1369 (2014): 52–63.
M. Zhao, X.‐J. Wu, Y.‐X. Fan, B.‐N. Guo, and J. Zhang, “Development and Validation of a UHPLC–MS/MS Assay for Colistin Methanesulphonate (CMS) and Colistin in Human Plasma and Urine Using Weak‐Cation Exchange Solid‐Phase Extraction,” Journal of Pharmaceutical and Biomedical Analysis 124 (2016): 303–308.
K. Bihan, Q. Lu, M. Enjalbert, et al., “Determination of Colistin and Colistimethate Levels in Human Plasma and Urine by High‐Performance Liquid Chromatography–Tandem Mass Spectrometry,” Therapeutic Drug Monitoring 38 (2016): 796–803.
G. Cangemi, S. Barco, E. Castagnola, G. Tripodi, F. Favata, and A. D'Avolio, “Development and Validation of UHPLC–MS/MS Methods for the Quantification of Colistin in Plasma and Dried Plasma Spots,” Journal of Pharmaceutical and Biomedical Analysis 129 (2016): 551–557.
N. H. Binhashim, S. N. Alvi, and M. M. Hammami, “LC‐MS/MS Method for Determination of Colistin in Human Plasma: Validation and Stability Studies,” International Journal of Analytical Mass Spectrometry and Chromatography 09 (2021): 1–11.
K. M. Matar and B. Al‐Refai, “Quantification of Colistin in Plasma by Liquid Chromatography‐Tandem Mass Spectrometry: Application to a Pharmacokinetic Study,” Scientific Reports 10 (2020): 8198.
B. Qi, M. Gijsen, P. Van Brantegem, et al., “Quantitative Determination of Colistin A/B and Colistin Methanesulfonate in Biological Samples Using Hydrophilic Interaction Chromatography Tandem Mass Spectrometry,” Drug Testing and Analysis 12 (2020): 1183–1195.
C. Cheng, S. Liu, D. Xiao, et al., “LC–MS/MS Method Development and Validation for the Determination of Polymyxins and Vancomycin in Rat Plasma,” Journal of Chromatography B 878 (2010): 2831–2838.
X. Wang, Q. Sun, X. Li, G. Wang, B. Xing, and Z. Li, “Novel Method for Determination of Colistin Sulfate in Human Plasma by High‐Performance Liquid Chromatography‐Tandem Mass Spectrometry and Its Clinical Applications in Critically Ill Patients,” Journal of Pharmacological and Toxicological Methods 127 (2024): 107502.
Y.‐C. Ma, X.‐K. Wu, X.‐L. Yang, and Z.‐Q. Zhang, “Simultaneous Determination of Colistin Sulfate and Tigecycline in Human Plasma by Liquid Chromatography‐Tandem Mass Spectrometry Method,” BMC Chemistry 18 (2024): 12.
S. K. Neef, A.‐D. Hinderer, W. Arbash, et al., “A High Performance Liquid Chromatography‐Tandem Mass Spectrometry Assay for Therapeutic Drug Monitoring of 10 Drug Compounds Commonly Used for Antimicrobial Therapy in Plasma and Serum of Critically Ill Patients: Method Optimization, Validation, Cross‐Validation and Clinical Application,” Clinica Chimica Acta 559 (2024): 119690.
A. R. Pinho, M. J. Rocha, G. Alves, A. C. Falcao, and A. C. Fortuna, “Development and Validation of an HPLC‐FLD Technique for Colistin Quantification and Its Plasma Monitoring in Hospitalized Patients,” Analytical Methods 10 (2018): 389–396.
Y. Hanai, K. Matsuo, T. Kosugi, et al., “Rapid, Simple, and Clinically Applicable High‐Performance Liquid Chromatography Method for Clinical Determination of Plasma Colistin Concentrations,” Journal of Pharmaceutical Health Care and Sciences 4 (2018): 22.
Y. Wang, X. Yu, C. Chen, et al., “Development of UPLC‐MS/MS Method for the Determination of Colistin in Plasma and Kidney Ad Its Application in Pharmacokinetics,” Journal of Pharmaceutical and Biomedical Analysis 233 (2023): 115440.
M. S. Zaidi, R. Abu Bakar, N. Musa, S. Mustafa, and W. N. W. Yusuf, “Optimization of Quadrupole Time‐Of‐Flight Liquid Chromatography Mass Spectrometry (QTOF‐LC/MS) Conditions for Determination of Colistin in Human Plasma,” Malaysian Journal of Analytical Sciences 26 (2022): 1288–1302.
H. Yuan, S. Yu, G. Chai, J. Liu, and Q. Zhou, “An LC‐MS/MS Method for Simultaneous Analysis of the Cystic Fibrosis Therapeutic Drugs Colistin, Ivacaftor and Ciprofloxacin,” Journal of Pharmaceutical Analysis 11 (2021): 732–738.
P. Chaisuwan, T. Moonta, A. Sangcakul, D. Nacapricha, P. Wilairat, and K. Uraisin, “Simple In‐House Flow‐Injection Capillary Electrophoresis With Capacitively Coupled Contactless Conductivity Method for the Determination of Colistin,” Journal of Separation Science 38 (2015): 1035–1041.
I. Cizmarova, V. Parrak, P. Secnik jr, et al., “A Simple and Green Capillary Electrophoresis‐Mass Spectrometry Method for Therapeutic Drug Monitoring of Colistin in Clinical Plasma Samples,” Heliyon 9 (2023): e23111.
K. H. Hee, Y. K. J. Leaw, J. L. Ong, and L. S. Lee, “Development and Validation of Liquid Chromatography Tandem Mass Spectrometry Method Quantitative Determination of Polymyxin B1, Polymyxin B2, Polymyxin B3 and Isoleucine‐Polymyxin B1 in Human Plasma and Its Application in Clinical Studies,” Journal of Pharmaceutical and Biomedical Analysis 140 (2017): 91–97.
M. Meng, L. Wang, S. Liu, et al., “Simultaneous Quantitation of Polymyxin B1, Polymyxin B2 and Polymyxin B1‐1 in Human Plasma and Treated Human Urine Using Solid Phase Extraction and Liquid Chromatography–tandem Mass Spectrometry,” Journal of Chromatography B 1012–1013 (2016): 23–36.
J. Covelli, D. Ruszaj, R. Straubinger, J. Li, and G. G. Rao, “The Development and Validation of a Simple Liquid Chromatography–tandem Mass Spectrometry Method for Polymyxin B1 and B2 Quantification in Different Matrices,” Journal of Chromatography B 1065–1066 (2017): 112–118.
T. A. Thomas, E. C. Broun, K. M. Abildskov, et al., “High Performance Liquid Chromatography‐Mass Spectrometry Assay for Polymyxin B1 and B2 in Human Plasma,” Therapeutic Drug Monitoring 34 (2012): 398–405.
J. He, S. Gao, M. Hu, D. S.‐L. Chow, and V. H. Tam, “A Validated Ultra‐Performance Liquid Chromatography–Tandem Mass Spectrometry Method for the Quantification of Polymyxin B in Mouse Serum and Epithelial Lining Fluid: Application to Pharmacokinetic Studies,” Journal of Antimicrobial Chemotherapy 68 (2013): 1104–1110.
X. Huang, X. Liu, Y. Wang, and J. Zhang, “Determination of Polymyxin B in Dried Blood Spots Using LC‐MS/MS for Therapeutic Drug Monitoring,” Journal of Chromatography B 1192 (2022): 123131.
X. Liu, Z. Yu, Y. Wang, et al., “Therapeutic Drug Monitoring of Polymyxin B by LC‐MS/MS in Plasma and Urine,” Bioanalysis 12 (2020): 845–855.
D. Liang, Z. Liang, G. Deng, et al., “Population Pharmacokinetic Analysis and Dosing Optimization of Polymyxin B in Critically Ill Patients,” Frontiers in Pharmacology 14 (2023): 1122310.
Y. Wang, J. Chen, J. Du, et al., “The Determination of Polymyxin B in Critically Ill Patients by HPLC‐MS/MS Method,” International Journal of Analytical Chemistry 2023 (2023): 6674009.
G. Cao, F. E. A. Ali, F. Chiu, A. P. Zavascki, R. L. Nation, and J. Li, “Development and Validation of a Reversed‐Phase High‐Performance Liquid Chromatography Assay for Polymyxin B in Human Plasma,” Journal of Antimicrobial Chemotherapy 62 (2008): 1009–1014.
P. Wang, Q. Zhang, Z. Qin, et al., “A Simple and Robust Liquid Chromatography With Tandem Mass Spectrometry Analytical Method for Therapeutic Drug Monitoring of Plasma and Cerebrospinal Fluid Polymyxin B1 and B2,” Therapeutic Drug Monitoring 42 (2020): 716–723.
M. A. Burkin, I. A. Galvidis, Y. A. Surovoy, I. V. Plyushchenko, I. A. Rodin, and S. V. Tsarenko, “Development of ELISA Formats for Polymyxin B Monitoring in Serum of Critically Ill Patients,” Journal of Pharmaceutical and Biomedical Analysis 204 (2021): 114275.
P. Panuwet, R. E. Hunter jr, P. E. D´Souza, et al., “Biological Matrix Effects in Quantitative Tandem Mass Spectrometry‐Based Analytical Methods: Advancing Biomonitoring,” Critical Reviews in Analytical Chemistry 46 (2016): 93–105.
M. H. Abdul‐Aziz, J.‐W.‐C. Alffenaar, M. Bassetti, et al., “Antimicrobial Therapeutic Drug Monitoring in Critically Ill Adult Patients: A Position Paper#,” Intensive Care Medicine 46 (2020): 1127–1153.
M.‐P. Avila, T. Pacheco, S. Arias, R.‐H. Bustos, J.‐C. Garcia, and D. Jaimes, “Is There a Role for the Therapeutic Drug Monitoring of colistin?: An Overview,” Pharmaceuticals 13 (2020): 42.
P. Radkowski, M. Derkaczew, M. Mazuchowski, et al., “Antibiotic‐Drug Interactions in the Intensive Care Unit: A Literature Review,” Antibiotics 13 (2024): 503.
C. Roger, “Understanding Antimicrobial Pharmacokinetics in Critically Ill Patients to Optimize Antimicrobial Therapy: A Narrative Review,” Journal of Intensive Medicine 4 (2024): 287–298.
I. Gerhardtova, I. Cizmarova, T. Jankech, et al., “Implementation of Modern Therapeutic Drug Monitoring and Lipidomics Approaches in Clinical Practice: A Case Study With Colistin Treatment,” Pharmaceuticals 17 (2024): 753.
A. Rúbies, I. Beguiristain, J. Tibon, N. Cortés‐Francisco, and M. Granados, “Analysing Polypeptide Antibiotics Residues in Animal Muscles Tissues: The Crucial Role of HRMS,” Food Chemistry 443 (2024): 138481.
R. Cusack, E. Little, and I. Martin‐Loeches, “Practical Lessons and Antimicrobial Therapy for Critically Ill Patients,” Antibiotics 13 (2024): 162.
F. R. DeLeo, M. Otto, B. N. Kreiswirth, and H. F. Chambers, “Community‐Associated Methicillin‐Resistant Staphylococcus aureus,” Lancet 375 (2010): 1557–1568.
I. Balakrishnan and R. J. Shorten, “Therapeutic Drug Monitoring of Antimicrobials,” Annals of Clinical Biochemistry 53 (2016): 333–346.
M. Kai, R. Tanaka, Y. Suzuki, et al., “Simultaneous Quantification of Plasma Levels of 12 Antimicrobial Agents Including Carbapenem, Anti‐Methicillin‐Resistant Staphylococcus aureus Agent, Quinolone and Azole Used in Intensive Care Unit Using UHPLC‐MS/MS Method,” Clinical Biochemistry 90 (2021): 40–49.
L. Tan, F. Deng, X. Luo, et al., “Glycosyl Imprinted Mesoporous Microspheres for the Determination of Glycopeptide Antibiotics Using Ultra‐High Performance Liquid Chromatography Coupled With Tandem Mass Spectrometry,” Journal of Chromatography A 1659 (2021): 462630.
J. Martens‐Lobenhoffer, J. T. Kielstein, C. Oye, and S. M. Bode‐Böger, “Validated High Performance Liquid Chromatography–UV Detection Method for the Determination of Daptomycin in Human Plasma,” Journal of Chromatography B 875 (2008): 546–550.
E. Gikas, F. N. Bazoti, P. Fanourgiakis, et al., “Simultaneous Quantification of Daptomycin and Rifampicin in Plasma by Ultra Performance Liquid Chromatography: Application to a Pharmacokinetic Study,” Journal of Pharmaceutical and Biomedical Analysis 51 (2010): 901–906.
P. Olszowy, M. Szultka, P. Fuchs, et al., “New Coated SPME Fibers for Extraction and Fast HPLC Determination of Selected Drugs in Human Blood,” Journal of Pharmaceutical and Biomedical Analysis 53 (2010): 1022–1027.
R. Cazorla‐Reyes, R. Romero‐González, A. G. Frenich, M. A. R. Maresca, and J. L. M. Vidal, “Simultaneous Analysis of Antibiotics in Biological Samples by Ultra High Performance Liquid Chromatography–Tandem Mass Spectrometry,” Journal of Pharmaceutical and Biomedical Analysis 89 (2014): 203–212.
M. Grégorie, A. G. Leroy, R. Bouquié, et al., “Simultaneous Determination of Ceftaroline, Daptomycin, Linezolid and Rifampicin Concentrations in Human Plasma by On‐Line Solid Phase Extraction Coupled to High‐Performance Liquid Chromatography–Tandem Mass Spectrometry,” Journal of Pharmaceutical and Biomedical Analysis 118 (2016): 17–26.
R. Tanaka, M. Kai, K. Goto, et al., “High‐Throughput and Wide‐Range Simultaneous Determination of Linezolid, Daptomycin and Tedizolid in Human Plasma Using Ultra‐Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry,” Journal of Pharmaceutical and Biomedical Analysis 194 (2021): 113764.
P. Seraissol, T. Lanot, S. Baklouti, et al., “Evaluation of 4 Quantification Methods for Monitoring 16 Antibiotics and 1 Beta‐Lactamase Inhibitor in Human Serum by High‐Performance Liquid Chromatography With Tandem Mass Spectrometry Detection,” Journal of Pharmaceutical and Biomedical Analysis 219 (2022): 114900.
J.‐F. Jourdill, J. Tonini, and F. Stanke‐Labesque, “Simultaneous Quantitation of Azole Antifungals, Antibiotics, Imatinib, and Raltegravir in Human Plasma by Two‐Dimensional High‐Performance Liquid Chromatography–tandem Mass Spectrometry,” Journal of Chromatography B 919–920 (2013): 1–9.
M. Szultka, R. Krzeminski, M. Jackowski, and B. Buszewski, “Simultaneous Determination of Selected Chemotherapeutics in Human Whole Blood by Molecularly Imprinted Polymers Coated Solid Phase Microextraction Fibers and Liquid Chromatography–tandem Mass Spectrometry,” Journal of Chromatography B 940 (2013): 66–76.
M. Dei Cas, E. Casagni, V. Gambaro, E. Cesari, and G. Roda, “Determination of Daptomycin in Human Plasma and Breast Milk by UPLC/MS‐MS,” Journal of Chromatography B 1116 (2019): 38–43.
S. Magréault, F. Jaureguy, J.‐R. Zahar, et al., “Automated HPLC‐MS/MS Assay for the Simultaneous Determination of Ten Plasma Antibiotic Concentrations,” Journal of Chromatography B 1211 (2022): 123496.
E. Gikas, F. N. Bazoti, P. Fanourgiakis, et al., “Development and Validation of a UPLC‐UV Method for the Determination of Daptomycin in Rabbit Plasma,” Biomedical Chromatography 24 (2010): 522–527.
T. Naito, T. Yamada, T. Yagi, and J. Kawakami, “Simple and Validated UHPLC Method Coupled to UV Detection for Determination of Daptomycin in Human Plasma and Urine,” Biomedical Chromatography 28 (2014): 317–319.
C. M. Tobin, J. M. Darville, A. M. Lovering, and A. P. MacGowan, “An HPLC Assay for Daptomycin in Serum,” Journal of Antimicrobial Chemotherapy 62 (2008): 1462–1463.
L. Liu, L. Zhang, X. Zheng, X. Liu, W. Liu, and J. Wu, “LC–MS/MS‐Based Multiplex Antibacterial Platform for Therapeutic Drug Monitoring in Intensive Care Unit Patients,” Frontiers in Pharmacology 14 (2023): 1116071.
H. Sun, H. Xing, X. Tian, X. Zhang, J. Yang, and P. Wang, “UPLC‐MS/MS Method for Simultaneous Determination of 14 Antimicrobials in Human Plasma and Cerebrospinal Fluid: Application to Therapeutic Drug Monitoring,” Journal of Analytical Methods in Chemistry 2022 (2022): 7048605.
H. G. Gika, F. Michopoulos, D. Divanis, S. Metalidis, P. Nikolaidis, and G. A. Theodoridis, “Daptomycin Determination by Liquid Chromatography–mass Spectrometry in Peritoneal Fluid, Blood Plasma, and Urine of Clinical Patients Receiving Peritoneal Dialysis Treatment,” Analytical and Bioanalytical Chemistry 397 (2010): 2191–2197.
M. Szultka, J. Szeliga, M. Jackowski, and B. Buszewski, “Development of Novel Molecularly Imprinted Solid‐Phase Microextraction Fibers and Their Application for the Determination of Antibiotic Drugs in Biological Samples by SPME‐LC/MSn,” Analytical and Bioanalytical Chemistry 403 (2012): 785–796.
M.‐C. Verdier, D. Bentué‐Ferrer, O. Tribut, N. Collet, M. Revest, and E. Bellissant, “Determination of Daptomycin in Human Plasma by Liquid Chromatography‐Tandem Mass Spectrometry. Clinical Application,” Clinical Chemistry and Laboratory Medicine 49 (2011): 69–75.
A. P. Sattur, J. H. Lee, K. B. Song, et al., “Analytical Techniques for vancomycin—A Review,” Biotechnology and Bioprocess Engineering 5 (2000): 153–158.
M. Vila, R. M. de Oliveira, M. M. Goncalves, and M. Tubino, “Analytical Methods for Vancomycin Determination in Biological Fluids and in Pharmaceuticals,” Química Nova 30 (2007): 395–399.
L. Javorska, L. Kujovska Krcmova, P. Solich, and M. Kaska, “Modern Methods for Vancomycin Determination in Biological Fluids by Methods Based on High‐Performance Liquid Chromatography—A Review,” Journal of Separation Science 39 (2016): 6–20.
I. Furuta, T. Kitahashi, T. Kuroda, H. Nishio, C. Oka, and Y. Morishima, “Rapid Serum Vancomycin Assay by High‐Performance Liquid Chromatography Using a Semipermeable Surface Packing Material Column,” Clinica Chimica Acta 301 (2000): 31–39.
M. Oyeart, N. Peersman, D. Kieffer, et al., “Novel LC–MS/MS Method for Plasma Vancomycin: Comparison With Immunoassays and Clinical Impact,” Clinica Chimica Acta 441 (2015): 63–70.
H. Brozmanová, I. Kacířová, R. Uřinovská, P. Šištík, and M. Grundmann, “New Liquid Chromatography‐Tandem Mass Spectrometry Method for Routine TDM of Vancomycin in Patients With both Normal and Impaired Renal Functions and Comparison With Results of Polarization Fluoroimmunoassay in Light of Varying Creatinine Concentrations,” Clinica Chimica Acta 469 (2017): 136–143.
S. Bahmany, M. Hassanzai, R. B. Flint, H. A. W. van Onzenoort, B. C. M. de Winter, and B. C. P. Koch, “Dried Blood Spot Analysis for the Quantification of Vancomycin and Creatinine Using Liquid Chromatography—Tandem Mass Spectrometry: Method Development and Validation,” Clinica Chimica Acta 553 (2024): 117689.
A. C. C. da Silva, L. de Lima Feltraco Lizot, M. F. Bastiani, M. V. Antunes, N. Brucker, and R. Linden, “Ready for TDM: Simultaneous Quantification of Amikacin, Vancomycin and Creatinine in Human Plasma Employing Ultra‐Performance Liquid Chromatography‐Tandem Mass Spectrometry,” Clinical Biochemistry 70 (2019): 39–45.
Y. Sheng and B. Zhou, “High‐Throughput Determination of Vancomycin in Human Plasma by Acost‐Effective System of Two‐Dimensional Liquid Chromatography,” Journal of Chromatography A 1409 (2017): 48–56.
P. Milla, F. Ferrari, E. Muntoni, M. Sartori, C. Ronco, and S. Arpicco, “Validation of a Simple and Economic HPLC‐UV Method for the Simultaneous Determination of Vancomycin, Meropenem, Piperacillin and Tazobactam in Plasma Samples,” Journal of Chromatography B 1148 (2020): 122151.
S. Shokouhi and I. A. Darazam, “Determination of Vancomycin Trough Level in Serum and Cerebrospinal Fluid of Patients With Acute Community‐Acquired Meningitis: A Prospective Study,” Journal of Infection 69 (2014): 424–429.
N. B. Andriguetti, L. L. Lisboa, S. R. Hahn, L. R. Pagnussat, M. V. Antunes, and R. Linden, “Simultaneous Determination of Vancomycin and Creatinine in Plasma Applied to Volumetric Absorptive Microsampling Devices Using Liquid Chromatography‐Tandem Mass Spectrometry,” Journal of Pharmaceutical and Biomedical Analysis 165 (2019): 315–324.
M. Zhang, X. L. Huang, Y. Wu, et al., “A Rapid and Simple UPLC Method for Serum Vancomycin Determination in Pediatric Patients Undergoing Continuous Infusion or Intermittent Infusion of Vancomycin,” Journal of Pharmaceutical and Biomedical Analysis 174 (2019): 214–219.
M. Sauter, P. Uhl, K. I. Foerster, et al., “An Ultra‐sensitive UHPLC‐MS/MS Assay for the Quantification of Orally Administered Vancomycin in Plasma,” Journal of Pharmaceutical and Biomedical Analysis 174 (2019): 633–638.
D. Ramadon, A. J. Courtenay, A. D. Permana, et al., “A Sensitive HPLC‐UV Method for Quantifying Vancomycin in Biological Matrices: Application to Pharmacokinetic and Biodistribution Studies in Rat Plasma, Skin and Lymph Nodes,” Journal of Pharmaceutical and Biomedical Analysis 189 (2020): 113429.
Y. Qi and G. Liu, “A UPLC‐MS/MS Method for Simultaneous Determination of Eight Special‐grade Antimicrobials in Human Plasma and Application in TDM,” Journal of Pharmaceutical and Biomedical Analysis 220 (2022): 114964.
K. Berthoin, E. Ampe, P. M. Tulkens, and S. Carryn, “Correlation Between Free and Total Vancomycin Serum Concentrations in Patients Treated for Gram‐positive Infections,” International Journal of Antimicrobial Agents 34 (2009): 555–560.
L. Scribel, A. P. Zavascki, D. Matos, et al., “Vancomycin and Creatinine Determination in Dried Blood Spots: Analytical Validation and Clinical Assessment,” Journal of Chromatography B 1137 (2020): 121897.
J. Xiao, J. Shi, R. Li, et al., “Developing a SWATH Capillary LC‐MS/MS Method for Simultaneous Therapeutic Drug Monitoring and Untargeted Metabolomics Analysis of Neonatal Plasma,” Journal of Chromatography B 1179 (2021): 122865.
X. Jiang, Y. Qin, R. Lei, et al., “A Rapid and Simple HPLC‐MS/MS Method for the Therapeutic Drug Monitoring of Six Special‐grade Antimicrobials in Pediatric Patients,” Heliyon 10 (2024): e24198.
F. Ibrahim, M. S. Elgawish, E. Mehaa, et al., “Toxicity Profile and Pharmacokinetic Study of Antibiotic Mixtures, Gentamicin and Vancomycin, in Rat Plasma by Ecofriendly Liquid Chromatography Coupled Tandem Mass Spectrometry,” Chem. Res. Toxicol. 33 (2020): 2647–2658.
K. König, U. Kobold, G. Fink, et al., “Quantification of Vancomycin in Human Serum by LC‐MS/MS,” Clinical Chemistry and Laboratory Medicine 51 (2013): 1761–1769.
Y. Fan, X. Peng, J. Yu, et al., “An Ultra‐performance Liquid Chromatography–Tandem Mass Spectrometry Method to Quantify Vancomycin in Human Serum by Minimizing the Degradation Product and Matrix Interference,” Bioanalysis 11 (2019): 941–955.
N. Brasier, A. Widmer, M. Osthoff, et al., “The Detection of Vancomycin in Sweat: A next‐generation Digital Surrogate Marker for Antibiotic Tissue Penetration: A Pilot Study,” Digital Biomarkers 5 (2021): 24–28.
P. Ghasemiyeh, A. Vazin, F. Zand, A. Azadi, I. Karimzadeh, and S. Mohammadi‐Samani, “A Simple and Validated HPLC Method for Vancomycin Assay in Plasma Samples: The Necessity of TDM Center Development in Southern Iran,” Research in Pharmaceutical Sciences 15 (2020): 529–540.
S. Barco, E. Castagnola, I. Gennai, et al., “Ultra High Performance Liquid Chromatography‐tandem Mass Spectrometry vs. commercial Immunoassay for Determination of Vancomycin Plasma Concentration in Children. Possible Implications for Everyday Clinical Practice,” Journal of Chemotherapy 28 (2016): 395–402.
F. Ren, Y. Liu, S. Li, et al., “Therapeutic Drug Monitoring of Free Vancomycin Concentration in Practice: A New Analytical Technique Based on the HFCF–UF Sample Separation Method,” Biomedical Chromatography 37 (2023): e5559.
F. R. Vidal, D. S. Ossanes, L. Birk, et al., “Development and Validation of a Dried Plasma Spot LC–MS/MS Method for Therapeutic Monitoring of Vancomycin and Comparison With Enzyme‐Multiplied Immunoassay,” Biomedical Chromatography 37 (2023): e5586.
T. de Mendonca Lima, K. S. Seba, J. C. S. Goncalves, F. L. L. Cardoso, C. E. de, and R. Estrela, “A Rapid and Simple HPLC Method for Therapeutic Monitoring of Vancomycin,” Journal of Chromatographic Science 56 (2018): 115–121.
M. Shi, X. Zhao, T. Wang, L. Yin, and Y. Li, “A LC–MS‐MS Assay for Simultaneous Determination of Two Glycopeptides and Two Small Molecule Compounds in Human Plasma,” Journal of Chromatographic Science 56 (2018): 828–834.
Y. Cao, J. Yu, Y. Chen, et al., “Development and Validation of a New Ultra‐Performance Liquid Chromatographic Method for Vancomycin Assay in Serum and Its Application to Therapeutic Drug Monitoring,” Therapeutic Drug Monitoring 36 (2014): 175–181.
W. Lu, M. Pan, H. Ke, et al., “An LC‐MS/MS Method for the Simultaneous Determination of 18 Antibacterial Drugs in Human Plasma and Its Application in Therapeutic Drug Monitoring,” Frontiers in Pharmacology 13 (2022): 1044234.
X. Chen, L. Du, and M. Liu, “Development, Validation, and Application of an UPLC‐MS/MS Method for Vancomycin, Norvancomycin, Methotrexate, Paclitaxel, and Imatinib Analysis in Human Plasma,” Annals of Clinical Biochemistry 59 (2022): 253–263.
Y. Fan, X. Peng, H. Wu, et al., “Simultaneous Separation and Determination of Vancomycin and Its Crystalline Degradation Products in Human Serum by Ultra High Performance Liquid Chromatography Tandem Mass Spectrometry Method and Its Application in Therapeutic Drug Monitoring,” Journal of Separation Science 43 (2020): 3987–3994.
J. Huo, Y. Guo, B. Zhang, Z. Zhao, G. Shi, and S. Mei, “A UHPLC–MS/MS Method for the Simultaneous Determination of Vancomycin, Norvancomycin, Meropenem, and Moxalactam in Human Plasma and Its Clinical Application,” Journal of Mass Spectrometry 58 (2023): e4925.
R. T. Cass, J. S. Villa, and D. E. Karr, “Rapid Bioanalysis of Vancomycin in Serum and Urine by High‐Performance Liquid Chromatography Tandem Mass Spectrometry Using On‐Line Sample Extraction and Parallel Analytical Columns,” Rapid Communications in Mass Spectrometry 15 (2001): 406–412.
M. Usman and G. Hempel, “Development and Validation of an HPLC Method for the Determination of Vancomycin in Human Plasma and Its Comparison With an Immunoassay (PETINIA),” SpringerPlus 5 (2016): 124.
Y. Li, L. Yin, Y. Li, et al., “Therapeutic Drug Monitoring of Vancomycin and Voriconazole by Liquid Chromatography‐Tandem Mass Spectrometric Method,” Chemical Research in Chinese Universities 33 (2017): 339–342.
S. Kanji, J. A. Roberts, J. Xie, et al., “Vancomycin Population Pharmacokinetics in Critically Ill Adults During Sustained Low‑Efficiency Dialysis,” Clinical Pharmacokinetics 59 (2020): 327–334.
G. Morikawa, K. Fukami, Y. Moriiwa, K. Okazawa, and A. Yanagida, “Evaluation of the Clinical and Quantitative Performance of a Practical HPLC‐UV Platform for In‐Hospital Routine Therapeutic Drug Monitoring of Multiple Drugs,” Journal of Pharmaceutical Health Care and Sciences 9 (2023): 29.
T. Ohtsuki, Y. Huang, A. Kamiya, et al., “Development of an HPLC Method Using Relative Molar Sensitivity for the Measurement of Blood Concentrations of Nine Pharmaceutical Compounds,” Journal of Pharmaceutical Health Care and Sciences 10 (2024): 35.
K. Todoroki, N. Fukudo, Y. Kudoh, et al., “Development of an On‐Site Therapeutic Drug Monitoring Method Using a Portable Spectrometer,” Analytical Sciences 40 (2024): 863–869.
M. N. Akram, M. I. Khokhar, M. Abbas, et al., “Therapeutic Drug Monitoring of Vancomycin in Surgical Patients Using a Validated HPLC Method,” International Journal of Clinical Pharmacology and Therapeutics 62 (2024): 259–266.
G. Yuan, H. Liu, A. S. Shaikh, et al., “Comparison of New Liquid Chromatography‐Mass Spectrometry Method and Enzyme‐Multiplied Immunoassay Technique for Routine Therapeutic Drug Monitoring of Vancomycin in Chinese Patients,” Clinical Laboratory 64 (2018): 277–285.
G. S. Moorthy, K. J. Downes, C. Vedar, and A. F. Zuppa, “A Whole Blood Microsampling Assay for Vancomycin: Development, Validation and Application for Pediatric Clinical Study,” Bioanalysis 12 (2020): 1295–1310.
F. Fang, N. Li, C. Xu, R. Tan, J. Yang, and Z. Zheng, “An UHPLC‐UV Method for the Determination of Vancomycin in Human Serum,” Current Pharmaceutical Analysis 17 (2021): 847–852.
G. Yuan, D. Liu, F. Bu, Y. Wang, B. Wang, and R. Guo, “LC‐MS for Simultaneous Determination of Vancomycin and Teicoplanin in Patient Plasma and Its Application to Therapeutic Drug Monitoring,” Current Pharmaceutical Analysis 15 (2019): 95–102.
Y. Bijleveld, T. R. de Haan, J. Toersche, et al., “A Simple Quantitative Method Analysing Amikacin, Gentamicin, and Vancomycin Levels in Human Newborn Plasma Using Ion‐Pair Liquid Chromatography/Tandem Mass Spectrometry and Its Applicability to a Clinical Study,” Journal of Chromatography B 951–952 (2014): 110–118.
K. H. Abu‐Shandi, “Determination of Vancomycin in Human Plasma Using High‐Performance Liquid Chromatography With Fluorescence Detection,” Analytical and Bioanalytical Chemistry 395 (2009): 527–532.
T. Kitahashi and I. Furuta, “Determination of Vancomycin in Human Serum by Micellar Electrokinetic Capillary Chromatography With Direct Sample Injection,” Clinica Chimica Acta 312 (2001): 221–225.
N. Spooner, P. Denniff, L. Michielsen, et al., “A Device for Dried Blood Microsampling in Quantitative Bioanalysis: Overcoming the Issues Associated Blood Hematocrit,” Bioanalysis 7 (2015): 653–659.
A. T. Roemmelt, A. E. Stauer, M. Poetzsch, and T. Kraemer, “Liquid Chromatography, in Combination With a Quadrupole Time‐Of‐Flight Instrument (LC QTOF), With Sequential Window Acquisition of all Theoretical Fragment‐Ion Spectra (SWATH) Acquisition: Systematic Studies on Its Use for Screenings in Clinical and Forensic Toxicology and Comparison With Information‐Dependent Acquisition (IDA),” Analytical Chemistry 86 (2014): 11742–11749.
A. Musenga, R. Mandrioli, V. Zecchi, B. Luppi, S. Fanali, and M. S. Raggi, “Capillary Electrophoretic Analysis of the Antibiotic Vancomycin in Innovative Microparticles and in Commercial Formulations,” Journal of Pharmaceutical and Biomedical Analysis 42 (2006): 32–38.
C. Lucas, J. P. Foley, and E. S. Ahuja, “Analysis of Glycopeptide Antibiotics Using Micellar Electrokinetic Chromatography and Borate Complexation,” Biomedical Chromatography 17 (2003): 172–181.
M. Horká, M. Vykydalová, F. Růžička, et al., “CIEF Separation, UV Detection, and Quantification of Ampholytic Antibiotics and Bacteria From Different Matrices,” Analytical and Bioanalytical Chemistry 406 (2014): 6285–6296.
H. Nishi, T. Fukuyama, and M. Matsuo, “Separation and Determination of Aspoxicillin in Human Plasma by Micellar Electrokinetic Chromatography With Direct Sample Injection,” Journal of Chromatography 515 (1990): 245–255.
W. Thorman, A. Minger, S. Molteni, J. Caslavska, and P. Gebauer, “Determination of Substituted Purines in Body Fluid by Micellar Electrokinetic Capillary Chromatography With Direct Sample Injection,” Journal of Chromatography 593 (1992): 275–288.
M. Ulldemolins, J. A. Roberts, J. Rello, D. Paterson, and J. Lipman, “The Effects of Hypoalbuminaemia on Optimizing Antibiotic Dosing in Critically Ill Patients,” Clinical Pharmacokinetics 50 (2011): 99–110.
A. Borghi, C. Coronelli, L. Faniuolo, G. Allievi, R. Pallanza, and G. G. Gallo, “Teichomycins, New Antibiotics From Actinoplanes Teichomyceticus nov. Sp. IV. Separation and Characterization of the Components of Teichomycin (teicoplanin),” Journal of Antibiotics 37 (1984): 615–620.
Y.‐F. Zhang, X.‐J. Zheng, J. Tian, S. Hu, X.‐H. Bai, and X. Chen, “Determination of Teicoplanin in Human Plasma by Reverse Micelle Mediated Dispersive Liquid‐Liquid Microextraction With High Performance Liquid Chromatography,” Journal of Chromatography A 1643 (2021): 462058.
S. Davani, M. Bérard, B. Royer, J.‐P. Kantelip, and P. Muret, “Comparison of Fluorescence Polarization Immunoassay and High‐Performance Liquid Chromatography Methods for Assay of Teicoplanin: Can Correlation be Improved?,” Pathologie Et Biologie 52 (2004): 584–588.
D. Ferrari, M. Ripa, S. Premaschi, G. Banfi, A. Castagna, and M. Locatelli, “LC‐MS/MS Method for Simultaneous Determination of Linezolid, Meropenem, Piperacillin and Teicoplanin in Human Plasma Samples,” Journal of Pharmaceutical and Biomedical Analysis 169 (2019): 11–18.
N. Mochizuki, K. Ohno, T. Shimamura, H. Furukawa, S. Todo, and S. Kishino, “Quantitative Determination of Individual Teicoplanin Components in Human Plasma and Cerebrospinal Fluid by High‐Performance Liquid Chromatography With Electrochemical Detection,” Journal of Chromatography B 847 (2007): 78–81.
K.‐Y. Kim, S.‐H. Cho, Y.‐H. Song, M.‐S. Nam, and C.‐W. Kim, “Direct Injection LC–MS/MS Method for the Determination of Teicoplanin in Human Plasma,” Journal of Chromatography B 1008 (2016): 125–131.
O. Begou, A. Kontou, N. Raikos, et al., “An Ultra‐High Pressure Liquid Chromatography‐Tandem Mass Spectrometry Method for the Quantification of Teicoplanin in Plasma of Neonates,” Journal of Chromatography B 1047 (2017): 215–222.
X. Ma, Y. Zou, J. Zhong, S. Yu, and L. Qiu, “Integrated Identification‐Quantification (ID‐Quant) Workflow Utilizing UPLC‐QTOF‐MS for the Therapeutic Drug Monitoring of Multi‐Component Antibiotics Without Pure Standards: Validation Using teicoplanin,” Journal of Chromatography B 1240 (2024): 124132.
D. M. Mueller, A. von Eckardstein, and L. Saleh, “Quantification of Teicoplanin in Plasma by LC‐MS With Online Sample Clean‐Up and Comparison With QMS® Assay,” Clinical Chemistry and Laboratory Medicine 52 (2014): 879–887.
A. Stajić, J. Maksić, D. Maksić, G. Forsdahl, M. Medenica, and B. Jančić‐Stojanović, “Analytical Quality by Design‐Based Development and Validation of Ultra Pressure Liquid Chromatography/MS/MS Method for Glycopeptide Antibiotics Determination in Human Plasma,” Bioanalysis 10 (2018): 1861–1876.
K. Hanada, A. Kobayashi, Y. Okamori, T. Kimura, and H. Ogata, “Improved Quantitative Determination of Total and Unbound Concentrations of Six Teicoplanin Components in Human Plasma by High Performance Liquid Chromatography,” Biological & Pharmaceutical Bulletin 28 (2005): 2023–2025.
X.‐X. Wang, P.‐F. Jin, P.‐M. Li, et al., “Interlaboratory Analysis of Teicoplanin Plasma Concentration Assays Among Chinese Laboratories,” Journal of Clinical Pharmacy and Therapeutics 45 (2020): 983–990.
S. J. McCann, L. O. White, and B. Keevil, “Assay of Teicoplanin in Serum: Comparison of High‐Performance Liquid Chromatography and Fluorescence Polarization Immunoassay,” Journal of Antimicrobial Chemotherapy 50 (2002): 107–110.
F. H. Y. Fung, J. C. Y. Tang, J. P. P. Hopkins, J. J. Dutton, L. M. Bailey, and A. S. Davison, “Measurement of Teicoplanin by Liquid Chromatography‐Tandem Mass Spectrometry: Development of a Novel Method,” Annals of Clinical Biochemistry 49 (2012): 475–481.
H. Chae, J. J. Lee, K. Cha, et al., “Measurement of Teicoplanin Concentration With LC‐MS/MS Method Demonstrates the Usefulness of Therapeutic Drug Monitoring in Hematologic Patient Populations,” Therapeutic Drug Monitoring 40 (2018): 330–336.
J. Shen, Z. Jiao, Y. Zhou, H. Zhu, and Z. Song, “Quantification of Teicoplanin in Human Plasma by Liquid Chromatography With Ultraviolet Detection,” Chromatographia 65 (2007): 9–12.
I. L. Tsai, F.‐L. L. Wu, C.‐S. Gau, and C.‐H. Kuo, “Method Development for the Determination of Teicoplanin in Patient Serum by Solid Phase Extraction and Micellar Electrokinetic Chromatography,” Talanta 77 (2009): 1208–1216.
M. Giakoumaki, Y. Sarigiannis, and E. Hapeshi, “A Novel Sensitive Analytical Method for the Simultaneous Analysis of Vancomycin and Teicoplanin in Human Urine via Single High‐Performance Liquid Chromatography Coupled With Photodiode Array and Mass Spectrometry in Series,” Journal of Separation Science 45 (2022): 2566–2581.
J. Mula, F. Chiara, A. Manca, et al., “Analytical Validation of a Novel UHPLC‐MS/MS Method for 19 Antibiotics Quantification in Plasma: Implementation in a LC‐MS/MS Kit,” Biomedicine & Pharmacotherapy 163 (2023): 114790.
T. Alebic‐Kolbah, R. Demers, and L. Cojocaru, “Dalbavancin: Quantification in Human Plasma and Urine by a New Improved High Performance Liquid Chromatography–Tandem Mass Spectrometry Method,” Journal of Chromatography B 879 (2011): 2632–2641.
A. Destere, D. Merino, L. Bonesso, et al., “A HPLC‐DAD Method to Facilitate Large‐Scale Therapeutic Drug Monitoring of dalbavancin,” Journal of Chromatography B 1222 (2023): 123694.
U. Chiriac, H. Rau, O. R. Frey, et al., “Validation and Application of an HPLC‐UV Method for Routine Therapeutic Drug Monitoring of dalbavancin,” Antibiotics 11 (2022): 541.
R. Zhang, H. Polenakovik, I. A. B. Beltran, et al., “Emergence of Dalbavancin, Vancomycin, and Daptomycin Nonsusceptible Staphylococcus aureus in a Patient Treated With Dalbavancin: Case Report and Isolate Characterization,” Clinical Infectious Diseases 75 (2022): 1641–1644.
M. Cavaleri, S. Riva, A. Valagussa, et al., “Pharmacokinetics and Excretion of Dalbavancin in the Rat,” Journal of Antimicrobial Chemotherapy 55 (2005): ii31–ii35.
D. Zhou, L. Ping, Y. Hong, J. Shen, Q. Weng, and Q. He, “Simultaneous Quantification and Pharmacokinetic Study of Five Homologs of Dalbavancin in Rat Plasma Using UHPLC‐MS/MS,” Molecules 25 (2020): 4100.
R. Barone, M. Conti, P. G. Cojutti, M. Gatti, P. Viale, and F. Pea, “Fast and Simple Liquid Chromatography‐Isotope Dilution Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of Dalbavancin in Long‐Term Treatment of Subacute and/or Chronic Infections,” Pharmaceutics 15 (2023): 480.
U. Rappo, M. W. Dunne, S. Puttagunta, et al., “Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults After a Single 1,500‐Milligram Infusion,” Antimicrobial Agents and Chemotherapy 63 (2019): e01024–19.
V. Avantaneo, M. Antonucci, E. D. De Vivo, et al., “Validation and Clinical Application of a New Liquid Chromatography Coupled to Mass Spectrometry (HPLC‐MS) Method for Dalbavancin Quantification in Human Plasma,” Separations 8 (2021): 189.
G. J. Fetterly, C. M. Ong, S. M. Bhavnani, et al., “Pharmacokinetics of Oritavancin in Plasma and Skin Blister Fluid Following Administration of a 200‐Milligram Dose for 3 Days or a Single 800‐Milligram Dose,” Antimicrobial Agents and Chemotherapy 49 (2005): 148–152.
A. Kumar, H. J. Mann, M. Keshtgarpour, et al., “In Vitro Characterization of Oritavancin Clearance From Human Blood by Low‐Flux, High‐Flux, and Continuous Renal Replacement Therapy Dialyzers,” International Journal of Artificial Organs 34 (2011): 1067–1074.
D. Lehoux, V. Ostiguy, C. Cadieux, et al., “Oritavancin Pharmacokinetics and Bone Penetration in Rabbits,” Antimicrobial Agents and Chemotherapy 59 (2015): 6501–6505.
X. Wang, J. A. Paul, T. N. Nanovskaya, G. D. V. Hankins, and M. S. Ahmed, “Quantitative Determination of Telavancin in Pregnant Baboon Plasma by Solid‐Phase Extraction and LC–ESI–MS,” Journal of Pharmaceutical and Biomedical Analysis 98 (2014): 107–112.
S. L. Barriere, D. J. Farrell, P. R. Rhomberg, and R. N. Jones, “Serum Inhibitory and Bactericidal Activity of Telavancin in Non‐Infected Subjects With Severe Renal Impairment or End‐Stage Renal Disease,” Diagnostic Microbiology and Infectious Disease 80 (2014): 327–329.
M. R. Goldberg, S. L. Wong, J.‐P. Shaw, M. M. Kitt, and S. L. Barriere, “Single‐Dose Pharmacokinetics and Tolerability of telavancin in Elderly Men and Women,” Pharmacotherapy 30 (2010): 806–811.
G. Stroffolini, A. De Nicolò, A. Gavirahi, et al., “Clinical Effectiveness and Pharmacokinetics of dalbavancin in Treatment‐Experienced Patients With Skin, Osteoarticular, or Vascular Infections,” Pharmaceutics 14 (2022): 1882.
"Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in Vitro Diagnostic Medical Devices and Repealing Directive 98/79/EC and Commission Decision 2010/227/EU," 2017, https://eur‐lex.europa.eu/eli/reg/2017/746. Accessed July 28, 2024.
B. R. Lubbers, A. Schilhabel, C. M. Cobbaert, et al., “The New EU Regulation on in Vivo Diagnostic Medical Devices: Implications and Preparatory Actions for Diagnostic Laboratories,” HemaSphere 5 (2021): e568.
Y. Takada, H. Itoh, A. Paudel, S. Panthee, H. Hamamoto, K. Sekimizu, et al., “Discovery of Gramicidin A Analogues With Altered Activities by Multidimensional Screening of a One‐Bead‐One‐Compound Library,” Nature Communications 11 (2020): 4935.
M. Rybak, B. Lomaestro, J. C. Rotschafer, et al., “Therapeutic Monitoring of Vancomycin in Adult Patients: A Consensus Review of the American Society of Health‐System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists,” American Journal of Health‐System Pharmacy 66 (2009): 82–98.
D. Cattaneo, M. Fusi, M. Colaneri, et al., “Therapeutic Drug Monitoring of Dalbavancin in Real Life: A Two‐Year Experience,” Antibiotics 13 (2023): 20.
P. G. Cojutti, M. Rinaldi, M. Gatti, S. Tedeschi, P. Viale, and F. Pea, “Usefulness of Therapeutic Drug Monitoring in Estimating the Duration of Dalbavancin Optimal Target Attainment in Staphylococcal Osteoarticular Infections: A Proof‐Of‐CSoncept,” International Journal of Antimicrobial Agents 58 (2021): 106445.
T. P. Lodise, M. Redell, S. O. Armstrong, K. A. Sulham, and G. R. Corey, “Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results from the SOLO Clinical Trials,” Open Forum Infectious Diseases 4 (2017): ofw274.
W. E. Rose and P. R. Hutson, “A Two‐Dose Oritavancin Regimen Using Pharmacokinetic Estimation Analysis,” Drugs—Real World Outcomes 7 (2020): 36–40.
K. A. Cairns, I. J. Abbott, M. J. Dooley, A. Y. Peleg, T. N. Peel, and A. A. Udy, “The Impact of Daptomycin Therapeutic Drug Monitoring on Clinical Outcomes: A Systematic Review,” International Journal of Antimicrobial Agents 61 (2023): 106712.
A. Galar, P. Muñoz, M. Valerio, E. Cercenado, X. García‐González, A. Burillo, et al., “Current Use of Daptomycin and Systematic Therapeutic Drug Monitoring: Clinical Experience in a Tertiary Care Institution,” International Journal of Antimicrobial Agents 53 (2019): 40–48.